Ligases Enzyme Market Size (2024 - 2029)

Ligases Enzyme Market Analysis

The Ligase Enzyme Market is anticipated to record a CAGR of nearly 5.5% during the forecast period.

The COVID-19 pandemic had a notable effect on the ligases enzyme market during the pandemic period. There were many research studies providing insight into the applications of ligases enzyme for identifying potential targets of therapeutic strategies against COVID-19 that significantly impacted the market's growth. For instance, the NCBI article published in April 2021 mentioned that HECT family members of E3 ligases were likely novel biomarkers for COVID-19, as well as new possible targets of therapeutic strategy easily tested in clinical trials. Such studies proving the potential benefits of ligase enzymes in the therapeutic usage against COVID-19 significantly impacted the market's growth. In addition, the demand for the ligases enzyme is expected to remain intact due to the applications in various studies of mutant strains of COVID-19, thereby boosting the market's growth over the forecast period.

The growth of the ligase enzyme market may be attributed to the increasing prevalence of various infectious diseases and genetic birth disorders due to its potential diagnostic and therapeutic properties. For instance, as per the WHO data published in 2022, an estimated 10.6 million tuberculosis cases were recorded globally in 2021. Thus, the high prevalence rate of people with tuberculosis surges the demand for effective and early diagnosis, thereby driving the ligases enzyme market. Also, another WHO data published in 2022 found that between January 24 and February 6, 2022, approximately 12,368 people tested positive for influenza viruses, with 8,423 (68.1%) being categorized as influenza A and 3,945 (31.9%), as influenza B. There were nearly 2,483 (93.6%) influenza A viruses and 171 (6.4%) influenza A(H1N1) pdm09 subtypes (H3N2). Such incidences of infectious diseases globally are expected to drive the demand for ligases enzyme, thereby contributing to the growth of the market. Similarly, the advent of ligases as therapeutic interventions for cancer is also expected to be one of the crucial driving factors of the market. For instance, an NCBI research study published in March 2022 stated that small ubiquitin-like modifier (SUMO) relation is a reversible post-translational modification that plays an essential role in numerous aspects of cell physiology, including cell cycle regulation, DNA damage repair, and protein trafficking and turnover, both of which are crucial for cell homeostasis. Thus, such research studies proving the effective therapeutic benefits of ligase enzymes for cancer are also expected to boost the market's growth.

However, the risk of the high sensitivity of the enzyme is expected to hinder the market growth.

Ligases Enzyme Industry Segmentation

As per the scope of the report, ligases are specific types of enzymes that speed up the joining of two large molecules, such as DNA. These enzymes are extensively used in cloning, mutation detection, gene synthesis, and next-generation sequencing. Ligase enzymes are also used for correcting dysfunctions and a lack of DNA ligases in humans. 

The Ligases Enzyme Market is Segmented by Source (Microorganisms (Bacteria, Viruses, and Other Microorganisms), Animals, and Plants), Application (Polymerase Chain Reaction, Cloning, Mutation Detection, Next-generation Sequencing, and Drug Target), End User (Diagnostic Centers and Hospitals, and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (USD million) for the above segments.